Comparative Pharmacology of a Bis-Pivaloyloxymethyl Phosphonate Prodrug Inhibitor of Enolase after Oral and Parenteral Administration-Reference-Cited by-同舟云学术

Comparative Pharmacology of a Bis-Pivaloyloxymethyl Phosphonate Prodrug Inhibitor of Enolase after Oral and Parenteral Administration

Published:2023-01-06 Issue:2 Volume:6 Page:245-252
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Yan Victoria C.¹^ORCID,Barekatain Yasaman²^ORCID,Lin Yu-Hsi¹^ORCID,Satani Nikunj¹^ORCID,Hammoudi Naima¹,Arthur Kenisha¹,Georgiou Dimitra K.¹,Jiang Yongying³,Sun Yuting³,Marszalek Joseph R.⁴,Millward Steven W.¹^ORCID,Muller Florian L.¹^ORCID

Affiliation:

1. Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States

2. Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States

3. Institute of Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States

4. Center for Co-Clinical Trials, University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4000, United States

Funder

National Cancer Institute

Andrew Sabin Family Foundation

Uncle Kory Foundation

National Comprehensive Cancer Network

Cancer Prevention and Research Institute of Texas

Dr. Marnie Rose Foundation